Interview 2 May 2023
Generative AI in novel drug development
Within months of its release, ChatGPT is finding use in almost all industries, including biotech, pharma, and healthcare. ChatGPT and…
Interview
- Latest Posts
Interview 8 Mar 2023
Phacilitate’s Women in Advanced Therapies program supports women in science
Marlin Frechette is the chief quality and compliance officer at FUJIFILM Irvine Scientific. But she has another role. Frechette is…
Interview 8 Mar 2023
How to ensure gender diversity in clinical trials
Labiotech sat down with Alicia Staley, VP, patient engagement at Medidata, a Dassault Systèmes company, to discuss underrepresentation of women…
Interview 3 Mar 2023
Interview: how has the first gene therapy for hemophilia B transformed research?
Hemophilia B, a rare disease that affects more than 230,000 people worldwide is caused by the lack of or defective…
ADVERTISEMENT
Interview 17 Feb 2023
The benefits – and challenges – of in-house CAR T-cell therapy
The Sheba Medical Center in Israel has an advanced hemato-oncology center that offers in-house CAR T-cell therapy, the revolutionary immunotherapy…
Interview 1 Feb 2023
Foundation for the National Institutes of Health: partnering to tackle cancer
The Foundation for the National Institutes of Health (FNIH) takes on cancer through public-private research partnerships on prevention and early…
Interview 26 Jan 2023
Scopio on the future of telehematology
Through full-field digital cell morphology, Scopio Labs’ technology can automate the analysis of tens of thousands of cells at a…
Interview 24 Jan 2023
Watch: Queen’s University tackling antimicrobial resistance
One of the biggest global challenges facing healthcare systems is bacteria and viruses becoming resistant to drugs. Antimicrobial resistance (AMR)…
Interview 23 Jan 2023
Watch: pHion Therapeutics talks about next-generation mRNA vaccines
pHion Therapeutics is a U.K.-based vaccine development company. It is developing a pipeline of therapeutic and prophylactic vaccines focussed on…
Interview 19 Jan 2023
Interview: Proscia talks about digital pathology
Labiotech recently interviewed Nathan Buchbinder, chief product officer at Proscia, about digital pathology. AI has been a hot topic in…
Interview 14 Dec 2022
Sibylla Biotech: how physicists met biologists to discover new drugs
Discovering new drugs remains an inefficient, trial and error-based process. The founding team behind the Italian startup Sibylla Biotech explain…
Interview 5 Dec 2022
Interview: why the recently approved fecal microbiome product is causing a rumble
The news last week of the FDA approving Ferring Pharmaceuticals' first fecal microbiome product, Rebyota, caused quite a stir in…
Interview 29 Nov 2022
LAG-3: The next big checkpoint inhibitor target
Since their first approval a decade ago, immune checkpoint inhibitors have been gaining momentum in the treatment of cancer. The…
Interview 28 Nov 2022
Breaking barriers to gene therapies for childhood rare diseases
The majority of known rare genetic diseases affect children, and gene therapies could help them live normal lives. Miquel Vila-Perelló,…
Interview 23 Nov 2022
What recent mixed clinical results can teach about Alzheimer’s disease
2022 has provided mixed fortunes for companies aiming to slow Alzheimer’s disease. Ulrich Dauer, CEO of the German biotech Vivoryon,…
Interview 18 Nov 2022
How cardioids can usher in the next generation of drug discovery
The California-based Molecular Devices brings automated 3D cell culture and image analysis together with HeartBeat.bio’s cardioid technology to enable unique…
ADVERTISEMENT
Interview 14 Nov 2022
MaaT Pharma: leading the charge in microbiome therapeutics
The first generation of microbiome therapeutics is hitting its first approvals. Savita Bernal, chief business officer at the French biotech…
Interview 14 Nov 2022
In depth interview: AstraZeneca/Sanofi RSV drug Beyfortus
AstraZeneca and Sanofi’s Beyfortus (nirsevimab) has been approved in the European Union (EU) for the prevention of respiratory syncytial virus…
Interview 7 Nov 2022
AI could tackle pharmaceutical manufacturing bottlenecks
Artificial intelligence (AI) is making waves in the world of drug discovery. Rajiv Anand, founder and CEO of the firm…
Interview 31 Oct 2022
AI and biobanks could open the way to longevity treatments
The development of longevity treatments is hampered by a lack of biomarkers and validated drug targets. BioAge’s co-founder and CEO,…
